Close

Leerink Partners Says Exelixis (EXEL) Sell-Off on ESMO Abstracts 'Overdone'

Go back to Leerink Partners Says Exelixis (EXEL) Sell-Off on ESMO Abstracts 'Overdone'

Exelixis (EXEL) 30-day volatility at 106 compared to 60 from a month ago

September 28, 2016 12:19 PM EDT

Exelixis (NASDAQ: EXEL) is recently down 17% on cabozantinib and Opdivo data concerns. 30-day call option implied volatility of 106 compares to volatility of 60 from a month ago.

... More

Exelixis (EXEL) call volume and volatility spikes as shares fall 17%

September 28, 2016 11:55 AM EDT

Exelixis (NASDAQ: EXEL) October 14 and 16 calls are active on total call volume of 9K contracts (3K puts). October call option implied volatility is at 99, November is at 82; compared to its 52 week range of 46 to 98.

... More

UPDATE: Exelixis (EXEL) Falls to Session Low on Cabozantinib and Opdivo Data

September 28, 2016 11:46 AM EDT

(Updated - September 28, 2016 11:57 AM, 12.56 PM EDT)

Exelixis (NASDAQ: EXEL) shares dropped Wednesday, falling 20%. The decline was tied to concerns about cabozantinib and Opdivo data and a numerically lower objected response rate vs other drugs combinations in testing.

According to Bloomberg, Stifel analyst Stephen Willey said data precludes comparisons.

... More